2Maruyama A,Saito T,Hachitanda Y,et al.Cancer history and loss of MSH2and MLH1 protein expression in patients with endometrial hyperplasia.Int J Gynecol Cancer,2003,13(3):352～360.
3Ricci E,Moroni S,Parazzini F,et al.Risk factors for endometrial hyperplasia:results from a case-control study.Int J Gynecol Cancer,2002,12 (3):257～260.
5Ansbacher R,Advincula AP.Endometrial polyp secondary to tamoxifen therapy.Fertil Steril,2003,80(1):216～217.
6Semiglazov VF,Maksimov SIa,Bulgatova EA,et al.Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen.Vopr Onkol,2003,49(2):198～204.
7Mourits MJ,De Vries EG,Willemse PH,et al.Tamoxifen treatment and gynecologic side effects.Obstet Gynecol,2001,97(5 Pt 2):855～866.
8Horn LC,Schnurrbusch U,Bilek K,et al.Risk of progression in complex and atypical endometrial hyperplasia:clinicopathologic analysis in cases with and without progestogen treatment.Int J Gynecol Cancer,2004,14 (2):348～353.
9Vereide AB,Arnes M,Straume B,et al.Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia:a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone.Gynecol Oncol,2003,91 (3):526～533.
10Figueroa-Casas PR,Ettinger B,Delgado E,et al.Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.Menopause,2001,8(6):420～423.
